



## **Competitive Enzyme Immunoassay Kit Liraglutide**

Catalog No : **CEK 0130-03**

### **Background :**

**Liraglutide**, marketed under the brand name **Victoza/Saxenda**, is a long-acting glucagon-like peptide-1 (GLP-1) analog that has been developed by Novo\_Nordisk for the treatment of type 2 diabetes. The product was approved by the European Medicines Agency (EMA) on July 3, 2009. It has been launched Germany, Denmark and the United Kingdom. The timeline to market in the United States is less certain.

Studies to date suggest liraglutide improves control of blood glucose. It reduces meal-related hyperglycaemia (for 12 hours after administration) by increasing insulin secretion, delaying gastric emptying, and suppressing prandial glucagon secretion.

Liraglutide may have advantages over current therapies:

1. It acts in a glucose-dependent manner, meaning that it will stimulate insulin secretion only when blood glucose levels are higher than normal. Consequently, it shows negligible risk of hypoglycemia.
2. It has the potential for inhibiting apoptosis and stimulating regeneration of beta cells (seen in animal studies).
3. It decreases appetite and maintains body weight, as shown in a head-to-head study versus glimepiride.
4. It lowers blood triglyceride levels.
5. It has only mild and transient side effects, mainly gastrointestinal.

**Kit application:** CEK Liraglutide is a 96 wells competitive immunoassay Kit. It can apply for the analysis of liraglutide in serum, plasma, or tissue extracts in pharmacokinetics, peptide delivery study and other purposes. It is for research use only.

**Application Note :** Room Temperature, 3 hours assay, 50ul sample size

**Storage :** 2 – 5 ° C

**Detection Method :** Colorimetric

**Range :** 0.01-1000ng / ml

ED<sub>20</sub> : 0.29ng/ml

ED<sub>80</sub> : 88ng/ml

**Specificity :**

Liraglutide 100%


GLP-1(7-37) 50%

GLP-1(7-36) amide 0%

Glucagon 0%

GLP-2 0%

Typical Data



These standard curve is provided for demonstration only. A standard curve should be generated for each set of samples assayed